Vinai Gondi, MD, discusses efficacy and safety findings from the phase 2/3 NRG-CC003 trial of prophylactic cranial irradiation in patients with small cell lung cancer.
Melissa L. Johnson, MD, discusses findings from a subgroup analysis of outcomes with ifinatamab deruxtecan in patients with refractory small cell lung cancer, which she presented at the 2023 IASLC World Conference on Lung Cancer.
Melissa L. Johnson, MD, discusses the development of the seizure-related homolog protein 6–targeting antibody-drug conjugate ABBV-011 and outcomes with this agent in patients with small cell lung cancer.